Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: Preparation and in vitro analysis

International Journal of Nanomedicine

Volumn 5, Issue 1, 2010, Pages 525-532

  Sebak, Safaa ^a   Mirzaei, Maryam ^a   Malhotra, Meenakshi ^a   Kulamarva, Arun ^a   Prakash, Satya ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Encapsulation; HSA; Microcapsule; Nanomedicine; Nanotechnology; Tumor volumes

Indexed keywords

HUMAN SERUM ALBUMIN; NANOPARTICLE; NOSCAPINE; ANTINEOPLASTIC AGENT; NANOCAPSULE; SERUM ALBUMIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS LINKING; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; IN VITRO STUDY; NANOANALYSIS; NANOENCAPSULATION; NANOFABRICATION; NANOPHARMACEUTICS; PARTICLE SIZE; PH MEASUREMENT; PROCESS OPTIMIZATION; SLOW DRUG RELEASE; ZETA POTENTIAL; BREAST TUMOR; CELL SURVIVAL; CHEMISTRY; FEMALE; HUMAN; METABOLISM; NANOMEDICINE; SCANNING ELECTRON MICROSCOPY; TUMOR CELL LINE; ULTRASTRUCTURE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MICROSCOPY, ELECTRON, SCANNING; NANOCAPSULES; NANOMEDICINE; NANOPARTICLES; NOSCAPINE; PARTICLE SIZE; SERUM ALBUMIN;

EID: 79952116455     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S10443     Document Type: Article

References (36)

1. Gradishar WJ. Albumin-bound nanoparticle paclitaxel. Clin Adv Hematol Oncol. 2005;3(5):348-349.
2. Lee MK, Lim SJ, Kim CK. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials. 2007;28(12):2137-2146.
3. Damascelli B, Cantù G, Mattavelli F, et al. Intra-arterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer. 2001;92(10):2592-2602.
4. Ke Y, Ye K, Grossniklaus HE, Archer DR, et al. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Cancer Immunol Immunother. 2000;49(4-5):217-225.
5. Aneja R, Dhiman N, Idnani J, et al. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemother Pharmacol. 2007;60(6):831-839.
6. Hiser L, Herrington B, Lobert S. Effect of noscapine and vincristine combination on demyelination and cell proliferation in vitro. Leuk Lymphoma. 2008;49(8):1603-1609.
7. Jackson T, Chougule MB, Ichite N, Patlolla RR, Singh M. Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemother Pharmacol. 2008;63(1):117-126.
8. Dahlstrom B, Mellstrand T, Lofdahl C, Johansson M. Pharmacokinetic properties of noscapine. Eur J Clin Pharmacol. 1982;22(6):535-539.
9. Karlsson MO, Dahlström B, Eckernäs SÅ, Johansson MA. Tufvesson Alm A. Pharmacokinetics of oral noscapine. Eur J Clin Pharmacol. 1990; 39(3):275-279.
10. Winter CA, Flataker L. Toxicity studies on noscapine. Toxicol Appl Pharmacol. 1961;3(1):96-106.
11. Newcomb EW, Lukyanov Y, Smirnova I, Schnee T, Zagzag D. Noscapine induces apoptosis in human glioma cells by an apoptosis-inducing factor-dependent pathway. Anticancer Drugs. 2008;19(6):553-563.
12. Aneja R, Vangapandu SN, Lopus M, et al. Synthesis of microtubuleinterfering halogenated noscapine analogs that perturb mitosis in cancer cells followed by cell death. Biochem Pharmacol. 2006;72(4): 415-426.
13. Aneja R, Zhou J, Zhou B, Chandra R, Joshi HC. Treatment of hormonerefractory breast cancer: apoptosis and regression of human tumors implanted in mice. Mol Cancer Ther. 2006;5(9):2366-2377.
14. Aneja R, Vangapandu SN, Lopus M, Chandra R, Panda D, Joshi HC. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma. Mol Pharmacol. 2006;69(6):1801-1809.
15. Zhou J, Gupta K, Aggarwal S, et al. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. Mol Pharmacol. 2003;63(4):799-807.
16. Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev. 2008;60(8): 876-885.
17. Groneberg DA, Giersig M, Welte T, Pison U. Nanoparticle-based diagnosis and therapy. Curr Drug Targets. 2006;7(6):643-648.
18. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54(5):631-651.
19. Hung O. Drug transformation: Advances in drug delivery systems. Can J Anaesth. 2006;53:(11):1074-1077.
20. Jiang W, Kim BY, Rutka JT, Chan WC. Advances and challenges of nanotechnology-based drug delivery systems. Expert Opin Drug Deliv. 2007;4(6):621-633.
21. Lazorthes Y, Sallerin-Caute B, Verdie JC, Bastide R. Advances in drug delivery systems and applications in neurosurgery. Adv Tech Stand Neurosurg. 1991;18:143-192.
22. Moghimi SM, Hunter AC, Murray JC. Long-circulating and targetspecific nanoparticles: theory to practice. Pharmacol Rev. 2001;53(2): 283-318.
23. Tokuda Y. Antibodies as molecular target-based therapy: trastuzumab. Int J Clin Oncol. 2003;8(4):224-229.
24. Reddy KR. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother. 2000; 34(7-8):915-923.
25. Portney NG, Ozkan M. Nano-oncology: drug delivery, imaging, and sensing. Anal Bioanal Chem. 2006;384(3):620-630.
26. West JL, Halas NJ. Applications of nanotechnology to biotechnology commentary. Curr Opin Biotechnol. 2000;11(2):215-217.
27. Vogelson C. Advances in drug delivery systems. 2001. Available from: http://pubs.acs.org/subscribe/journals/mdd/v04/i04/html/MDD04FeatureVogelson.html
28. Weber C, Kreuter J, Langer K. Desolvation process and surface characteristics of HSA-nanoparticles. Int J Pharm. 2000;196(2): 197-200.
29. Lin W, Coombes AG, Davies MC, Davis SS, Illum L. Preparation of sub-100 nm human serum albumin nanospheres using a pH-coacervation method. J Drug Target. 1993;1(3):237-243.
30. Lin W, Garnett MC, Davis SS, Schacht E, Ferruti P, Illum L. Preparation and characterisation of rose Bengal-loaded surface-modified albumin nanoparticles. J Control Release. 2001;71(1):117-126.
31. Merodio M, Arnedo A, Renedo MJ, Irache JM. Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties. Eur J Pharm Sci. 2001;12(3):251-259.
32. Yuan H, Miao J, Du YZ, You J, Hu FQ, Zeng S. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm. 2008;348(1-2):137-145.
33. Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2/ neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene. 1997;15(8):953-960.
34. Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release. 2004;99(2):259-269.
35. Müller RH, Maassen S, Weyhers H, Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target. 1996;4(3): 161-170.
36. Rubino OP, Kowalsky R, Swarbrick J. Albumin microspheres as a drug delivery system: relation among turbidity ratio, degree of cross-linking, and drug release. Pharm Res. 1993;10(7):1059-1065.